» Authors » Eileen Baildam

Eileen Baildam

Explore the profile of Eileen Baildam including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 1265
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kearsley-Fleet L, Baildam E, Beresford M, Douglas S, Foster H, Southwood T, et al.
Lancet Rheumatol . 2024 Jun; 6(7):e438-e446. PMID: 38843858
Background: For cost-saving purposes, children and young people with juvenile idiopathic arthritis (JIA) are being switched (for non-medical reasons) from biological originators to biosimilars. Here, we aimed to investigate those...
2.
Kearsley-Fleet L, Baildam E, Beresford M, Douglas S, Foster H, Southwood T, et al.
Rheumatology (Oxford) . 2022 Sep; 62(5):1926-1935. PMID: 36104094
Objectives: Clinicians concerned about long-term safety of biologics in JIA may consider tapering or stopping treatment once remission is achieved despite uncertainty in maintaining drug-free remission. This analysis aims to...
3.
Brogan P, Arch B, Hickey H, Anton J, Iglesias E, Baildam E, et al.
Arthritis Rheumatol . 2021 Mar; 73(9):1673-1682. PMID: 33760371
Objective: Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study...
4.
Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al.
Rheumatology (Oxford) . 2020 Nov; 60(4):1651-1658. PMID: 33147624
Juvenile systemic sclerosis (JSSc) is a rare disease of childhood and currently no international consensus exists with regard to its assessment and treatment. This SHARE (Single Hub and Access point...
5.
Kearsley-Fleet L, Heaf E, Davies R, Baildam E, Beresford M, Foster H, et al.
Lancet Rheumatol . 2020 Apr; 2(4):e217-e226. PMID: 32280951
Background: Information is scarce about biological disease-modifying antirheumatic drug (DMARD) switching patterns in children and young people (aged ≤16 years) with juvenile idiopathic arthritis in an era of many biologic...
6.
Davies R, De Cock D, Kearsley-Fleet L, Southwood T, Baildam E, Beresford M, et al.
Rheumatology (Oxford) . 2019 Oct; 59(6):1391-1397. PMID: 31605484
Objectives: To describe and compare the occurrence of newly diagnosed uveitis in children with JIA receiving MTX, etanercept, adalimumab and infliximab. Methods: This on-drug analysis included patients within UK JIA...
7.
Shoop-Worrall S, Hyrich K, Verstappen S, Sergeant J, Baildam E, Chieng A, et al.
Arthritis Care Res (Hoboken) . 2019 Mar; 72(4):517-524. PMID: 30875458
Objective: In pediatric research, investigators rely on proxy reports of outcome, such as the proxy-completed Childhood Health Assessment Questionnaire (C-HAQ), to assess function in juvenile idiopathic arthritis (JIA). As children...
8.
Kearsley-Fleet L, Vicente Gonzalez L, Steinke D, Davies R, De Cock D, Baildam E, et al.
Rheumatology (Oxford) . 2019 Mar; PMID: 30851113
Objectives: This analysis aims to calculate MTX monotherapy persistence and describe the occurrence of and factors associated with the occurrence of adverse drug reactions (ADRs) with MTX. Methods: Patients with...
9.
Hendry G, Shoop-Worrall S, Riskowski J, Andrews P, Baildam E, Chieng A, et al.
Rheumatol Adv Pract . 2019 Jan; 2(2):rky039. PMID: 30627693
Objective: The aim was to investigate the time course of lower limb disease activity and walking disability in children with JIA over a 5-year course. Methods: The Childhood Arthritis Prospective...
10.
Sherratt F, Roper L, Stones S, McErlane F, Peak M, Beresford M, et al.
Pediatr Rheumatol Online J . 2018 Dec; 16(1):76. PMID: 30514320
Background: Patient recruitment can be very challenging in paediatric studies, especially in relatively uncommon conditions, such as juvenile idiopathic arthritis (JIA). However, involving children and young people (CYP) in the...